{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T06:41:42Z","timestamp":1777704102384,"version":"3.51.4"},"reference-count":40,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T00:00:00Z","timestamp":1646870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["72122001"],"award-info":[{"award-number":["72122001"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["71934002"],"award-info":[{"award-number":["71934002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: The proportion of children and adolescents with COVID-19 had gradually increased according to data reported by WHO. However, there was no meta-analysis of effectiveness and safety of SARS-CoV-2 vaccines in children and adolescents. We aimed to provide investigation-based medical evidence and reference recommendations for children and adolescents in regard to SARS-CoV-2 vaccines. Methods: We systematically searched PubMed, Embase, and Web of Science from inception to 5 January 2022. RCTs and observational studies that examined the effectiveness and safety were included. Results: A total of 13 eligible studies were included for analysis. For the first dose, the effectiveness of SARS-CoV-2 vaccines against SARS-CoV-2 infection and COVID-19 was 88.5% (95% CI:15.7\u201398.4%, p = 0.033) and 84.3% (95% CI: 66.6\u201392.6%, p &lt; 0.001) separately. For the second dose, the effectiveness against SARS-CoV-2 infection and COVID-19 was 91.6% (95% CI: 37.8\u201399.5%, p = 0.083) and 92.7 (95% CI: 82.2\u201397.0, p &lt; 0.001) separately. Injection-site pain, fatigue, headache, anorexia, and axillary swelling were the top five adverse events after the first dose of SARS-CoV-2 vaccines. Fatigue, injection-site pain, headache, chills, and myalgia\/muscle pain were the top five adverse events after the second dose of SARS-CoV-2 vaccines. Conclusions: SARS-CoV-2 vaccines had good effectiveness and safety in children and adolescents. We suggest that children and adolescents should get vaccinated as soon as possible to protect themselves and slow the spread of the pandemic.<\/jats:p>","DOI":"10.3390\/vaccines10030421","type":"journal-article","created":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T20:19:10Z","timestamp":1646943550000},"page":"421","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Effectiveness and Safety of SARS-CoV-2 Vaccines among Children and Adolescents: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"10","author":[{"given":"Peng","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Cai","sequence":"additional","affiliation":[{"name":"Institute of Child and Adolescent Health, School of Public Health, Peking University, Beijing 100191, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6958-2091","authenticated-orcid":false,"given":"Qiao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1938-9365","authenticated-orcid":false,"given":"Jue","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China"},{"name":"Institute for Global Health and Development, Peking University, Beijing 100871, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5059-3743","authenticated-orcid":false,"given":"Min","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,10]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2022, January 16). Coronavirus Disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update. Available online: https:\/\/covid19.who.int\/."},{"key":"ref_2","unstructured":"World Health Organization (2022, January 16). Therapeutics and COVID-19. Available online: https:\/\/www.who.int\/teams\/health-care-readiness\/covid-19\/therapeutics."},{"key":"ref_3","unstructured":"World Health Organization (2022, January 16). COVID-19 Advice for the Public: Getting Vaccinated. Available online: https:\/\/covid19.who.int\/."},{"key":"ref_4","unstructured":"World Health Organization (2022, January 16). WHO Coronavirus (COVID-19) Dashboard. Available online: https:\/\/covid19.who.int\/."},{"key":"ref_5","unstructured":"Centers for Disease Control and Prevention (2022, January 16). COVID Data Tracker, Available online: https:\/\/covid.cdc.gov\/covid-data-tracker\/#demographicsovertime."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Maldonado, Y.A., O\u2019Leary, S.T., Banerjee, R., Campbell, J.D., Caserta, M.T., Gerber, J.S., Kourtis, A.P., Lynfield, R., Munoz, F.M., and Nolt, D. (2021). COVID-19 vaccines in children and adolescents. Pediatrics, 148.","DOI":"10.1542\/peds.2021-052336"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1056\/NEJMoa2109522","article-title":"Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents","volume":"385","author":"Ali","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2107456","article-title":"Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents","volume":"385","author":"Frenck","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/S1473-3099(21)00319-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: A double-blind, randomised, controlled, phase 1\/2 clinical trial","volume":"21","author":"Han","year":"2021","journal-title":"Lancet Infect Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa2116298","article-title":"Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age","volume":"386","author":"Walter","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: A randomised, double-blind, controlled, phase 1\/2 trial","volume":"21","author":"Xia","year":"2021","journal-title":"Lancet Infect Dis."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Zhu, F., Jin, P., Zhu, T., Wang, W., Ye, H., Pan, H., Hou, L., Li, J., Wang, X., and Wu, S. (2021). Safety and immunogenicity of a recombinant adenovirus type-5-vectored COVID-19 vaccine with a homologous prime-boost regimen in healthy participants aged 6 years and above: A randomised, double-blind, placebo-controlled, phase 2b trial. Clin. Infect Dis., ciab845.","DOI":"10.1093\/cid\/ciab845"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(21)02183-8","article-title":"Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: A retrospective cohort study","volume":"398","author":"Tartof","year":"2021","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.15585\/mmwr.mm7031e1","article-title":"COVID-19 Vaccine Safety in Adolescents Aged 12\u201317 Years\u2014United States, 14 December 2020\u201316 July 2021","volume":"70","author":"Hause","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.15585\/mmwr.mm7042e1","article-title":"Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12\u201318 Years\u2014United States, June\u2013September 2021","volume":"70","author":"Olson","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1136\/archdischild-2021-322655","article-title":"Initial experience of the safety and tolerability of the BNT162b2 (Pfizer-Bio-N-Tech) vaccine in extremely vulnerable children aged 12\u201315 years","volume":"107","author":"King","year":"2021","journal-title":"Arch Dis Child."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Lv, M., Luo, X., Shen, Q., Lei, R., Liu, X., Liu, E., Li, Q., and Chen, Y. (2021). Safety, immunogenicity, and efficacy of COVID-19 vaccines in children and adolescents: A systematic review. Vaccines, 9.","DOI":"10.1101\/2021.09.11.21262855"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"ref_19","unstructured":"The Ottawa Hospital (2022, January 16). The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Available online: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"ref_20","unstructured":"Rostom, A., Dub\u00e9, C., Cranney, A., Saloojee, N., Sy, R., and Garritty, C. (2004). Celiac Disease, Agency for Healthcare Research and Quality. Evidence Reports\/Technology Assessments, No. 104. Appendix D. Quality Assessment Forms."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.15585\/mmwr.mm705152a2","article-title":"Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12\u201317 Years\u2014Arizona, July\u2013December 2021","volume":"70","author":"Lutrick","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months","volume":"385","author":"Thomas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s10787-021-00839-2","article-title":"Real-world effectiveness of BNT162b2 mRNA vaccine: A meta-analysis of large observational studies","volume":"29","author":"Kow","year":"2021","journal-title":"Inflammopharmacology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1056\/NEJMoa2113017","article-title":"Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase","volume":"385","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_26","unstructured":"World Health Organization (2022, March 04). Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. Available online: https:\/\/www.who.int\/news\/item\/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6059","DOI":"10.1016\/j.vaccine.2017.09.046","article-title":"A systematic review of factors affecting vaccine uptake in young children","volume":"35","author":"Smith","year":"2017","journal-title":"Vaccine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40249-021-00878-5","article-title":"Safety of SARS-CoV-2 vaccines: A systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Chen","year":"2021","journal-title":"Infect. Dis. Poverty"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40249-021-00915-3","article-title":"Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: A systematic review and meta-analysis","volume":"10","author":"Liu","year":"2021","journal-title":"Infect. Dis. Poverty"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1097\/INF.0000000000003389","article-title":"Population-based Incidence of Myopericarditis After COVID-19 Vaccination in Danish Adolescents","volume":"41","author":"Nygaard","year":"2022","journal-title":"Pediatric Infect. Dis. J."},{"key":"ref_31","first-page":"1255","article-title":"Hospitalizations Associated with COVID-19 Among Children and Adolescents\u2014COVID-NET, 14 States, 1 March 2020\u201314 August 2021","volume":"70","author":"Delahoy","year":"2021","journal-title":"MMWR Recomm. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Alamer, E., Alhazmi, A., Qasir, N.A., Alamer, R., Areeshi, H., Gohal, G., Qadri, M., Hashem, A.M., and Algaissi, A. (2021). Side Effects of COVID-19 Pfizer-BioNTech mRNA Vaccine in Children Aged 12\u201318 Years in Saudi Arabia. Vaccines, 9.","DOI":"10.3390\/vaccines9111297"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijid.2021.12.354","article-title":"Comparing self-reported reactogenicity between adolescents and adults following the use of BNT162b2 (Pfizer-BioNTech) messenger RNA Covid-19 vaccine: A prospective cohort study","volume":"116","author":"Chan","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Chua, G.T., Kwan, M.Y.W., Chui, C.S.L., Smith, R.D., Cheung, E.C.-L., Tian, T., Leung, M.T.Y., Tsao, S.S.L., Kan, E., and Ng, W.K.C. (2021). Epidemiology of Acute Myocarditis\/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.","DOI":"10.1093\/cid\/ciab989"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.15585\/mmwr.mm705152a1","article-title":"COVID-19 Vaccine Safety in Children Aged 5\u201311 Years\u2014United States, November 3-December 19, 2021","volume":"70","author":"Hause","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_36","first-page":"1361","article-title":"Expert consensus on New Coronavirus vaccination for children","volume":"36","author":"Zhijie","year":"2021","journal-title":"Chin. J. Appl. Clin. Pediatr."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3346\/jkms.2021.36.e227","article-title":"Pediatric and Parents\u2019 Attitudes Towards COVID-19 Vaccines and Intention to Vaccinate for Children","volume":"36","author":"Choi","year":"2021","journal-title":"J. Korean Med. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"7789","DOI":"10.1016\/j.vaccine.2020.10.027","article-title":"Parents\u2019 and guardians\u2019 views on the acceptability of a future COVID-19 vaccine: A multi-methods study in England","volume":"38","author":"Bell","year":"2020","journal-title":"Vaccine"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"997","DOI":"10.15585\/mmwr.mm7028e1","article-title":"Acceptability of Adolescent COVID-19 Vaccination Among Adolescents and Parents of Adolescents\u2014United States, 15\u201323 April 2021","volume":"70","author":"Scherer","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1007\/s00431-021-04094-z","article-title":"Parents\u2019 intention to get vaccinated and to have their child vaccinated against COVID-19: Cross-sectional analyses using data from the KUNO-Kids health study","volume":"180","author":"Brandstetter","year":"2021","journal-title":"Eur. J. Pediatrics"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/3\/421\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:34:23Z","timestamp":1760135663000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/3\/421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,10]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["vaccines10030421"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10030421","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,10]]}}}